Filtered By:
Specialty: Drugs & Pharmacology
Cancer: Non-Small Cell Lung Cancer

This page shows you your search results in order of date. This is page number 3.

Order by Relevance | Date

Total 91 results found since Jan 2013.

A bivalent cyclic RGD-siRNA conjugate enhances the antitumor effect of apatinib via co-inhibiting VEGFR2 in non-small cell lung cancer xenografts
Drug Deliv. 2021 Dec;28(1):1432-1442. doi: 10.1080/10717544.2021.1937381.ABSTRACTThe vascular endothelial growth factor receptor 2 (VEGFR2) is considered to be a pivotal target for anti-tumor therapy against angiogenesis of non-small cell lung cancer (NSCLC). However, effective and low-toxicity targeted therapies to inhibit VEGFR2 are still lacking. Here, biRGD-siVEGFR2 conjugate comprising murine VEGFR2 siRNA and [cyclo(Arg-Gly-Asp-D-Phe-Lys)-Ahx]2-Glu-PEG-MAL (biRGD) peptide which selectively binds to integrin αvβ3 receptors expressing on neovascularization endothelial cell was synthesized. The anti-tumor activity and ...
Source: Drug Delivery - July 8, 2021 Category: Drugs & Pharmacology Authors: Lumin Liao Bohong Cen Guoxian Li Yuanyi Wei Zhen Wang Wen Huang Shuai He Yawei Yuan Aimin Ji Source Type: research

Upregulation of wild-type p53 by small molecule-induced elevation of NQO1 in non-small cell lung cancer cells
Acta Pharmacol Sin. 2021 May 25. doi: 10.1038/s41401-021-00691-8. Online ahead of print.ABSTRACTThe tumor suppressor p53 is usually inactivated by somatic mutations in malignant neoplasms, and its reactivation represents an attractive therapeutic strategy for cancers. Here, we reported that a new quinolone compound RYL-687 significantly inhibited non-small cell lung cancer (NSCLC) cells which express wild type (wt) p53, in contract to its much weaker cytotoxicity on cells with mutant p53. RYL-687 upregulated p53 in cells with wt but not mutant p53, and ectopic expression of wt p53 significantly enhanced the anti-NSCLC acti...
Source: Acta Pharmacologica Sinica - May 26, 2021 Category: Drugs & Pharmacology Authors: Hong Yu Hong-Ying Gao Hua Guo Gui-Zhen Wang Yi-Qing Yang Qian Hu Li-Jun Liang Qun Zhao Da-Wei Xie Yu Rao Guang-Biao Zhou Source Type: research

Restricting Glutamine Uptake Enhances NSCLC Sensitivity to Third-Generation EGFR-TKI Almonertinib
The emergence of secondary resistance is the main failure cause of epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) as a targeted therapy for non-small cell lung cancer (NSCLC). EGFR mutations of NSCLC cells can markedly increase glutamine transporter (SLC1A5) expression, thereby increasing glutamine metabolism. Glutamine metabolites can activate EGFR downstream signals, including mTOR, ERK1/2, STAT3, etc., which is an important cause for the decreased sensitivity of NSCLC to EGFR-TKIs. CCK8 and Annexin V/PI assays were conducted to detect the effects of Almonertinib and/or V9302 on the proliferation...
Source: Frontiers in Pharmacology - May 14, 2021 Category: Drugs & Pharmacology Source Type: research

Inhibition of histamine receptor H3 suppresses the growth and metastasis of human non-small cell lung cancer cells via inhibiting PI3K/Akt/mTOR and MEK/ERK signaling pathways and blocking EMT.
In conclusion, this study reveals that Hrh3 plays an important role in the growth and metastasis of NSCLC; it might be a potential therapeutic target against the lung cancer. PMID: 33159174 [PubMed - as supplied by publisher]
Source: Acta Pharmacologica Sinica - November 6, 2020 Category: Drugs & Pharmacology Authors: Zhao YY, Jia J, Zhang JJ, Xun YP, Xie SJ, Liang JF, Guo HG, Zhu JZ, Ma SL, Zhang SR Tags: Acta Pharmacol Sin Source Type: research

Baicalein suppresses growth of non-small cell lung carcinoma by targeting MAP4K3.
Abstract Exploring key genes associated with non-small cell lung carcinoma (NSCLC) may lead to targeted therapies for NSCLC patients. The protein kinase MAP4K3 has been established as an important modulator of cell growth and autophagy in mammals. Herein, we investigated the somatic mutations and the expression pattern of MAP4K3 detected in NSCLC patients based on the TCGA database. Abnormal MAP4K3 expression and its somatic mutations are associated with the carcinogenesis and thereby becoming an attractive therapeutic target. Baicalein, a natural product, was determined to be the first-reported MAP4K3 binding l...
Source: Biomedicine and pharmacotherapy = Biomedecine and pharmacotherapie - November 6, 2020 Category: Drugs & Pharmacology Authors: Li J, Yan L, Luo J, Tong L, Gao Y, Feng W, Wang F, Cui W, Li S, Sun Z Tags: Biomed Pharmacother Source Type: research

Statement of Retraction.
Abstract Recently, we have found an anomaly of Fig 3B. The results of our invasion assay of A549 cells with transduction with the siRNA-control or the siRNA-KIF20A has shown that no significant suppression of cells infected with siRNA-KIF20A when compared with that of the siRNA-control cells. In this manuscript, this anomalous result was relevant to the conclusion, The KIF20A silence inhibits the invasion of non-small cell lung cancer. PMID: 33068446 [PubMed - as supplied by publisher]
Source: Clinical and Experimental Pharmacology and Physiology - October 17, 2020 Category: Drugs & Pharmacology Authors: Xie F, Gao S, He C, Li L, Qiao L Tags: Clin Exp Pharmacol Physiol Source Type: research

OTX1 is a novel regulator of proliferation, migration, invasion and apoptosis in lung adenocarcinoma.
CONCLUSIONS: Silencing the OTX1 gene suppressed the proliferation, migration and invasion of NCI-H292 and XWLC cells, impeded the cell cycle transition from G2 to M phase, and accelerated apoptosis, revealing OTX1, a regulator of NSCLC, as a potential new therapeutic target. PMID: 33015792 [PubMed - in process]
Source: European Review for Medical and Pharmacological Sciences - October 7, 2020 Category: Drugs & Pharmacology Tags: Eur Rev Med Pharmacol Sci Source Type: research

Effect of lncRNA-BLACAT1 on drug resistance of non-small cell lung cancer cells in DDP chemotherapy by regulating cyclin D1 expression.
CONCLUSIONS: LncRNA-BLACAT1 regulates the expression of Cyclin D1, reduces the malignant phenotype of drug-resistant cells, and increases the sensitivity of lung cancer cells to DDP. PMID: 33015788 [PubMed - in process]
Source: European Review for Medical and Pharmacological Sciences - October 7, 2020 Category: Drugs & Pharmacology Tags: Eur Rev Med Pharmacol Sci Source Type: research

The pH-triggered polyglutamate brush co-delivery of MDR1 and survivin-targeting siRNAs efficiently overcomes multi-drug resistance of NSCLC.
In this study, we attempted to overcome MDR of NSCLC by simultaneously interfering with two RNAs that have different functions. A new pH-triggered polyglutamate brush polymer dimethylmaleic anhydride-poly(ethyleneglycol) monomethyl ether-b-polyglutamate-g-spermine (DMA-mPEG-b-PG-g-spermine, DPPGS) was designed and synthesized. The DPPGS/small interfering RNA (siRNA) complex nanoparticles (DPPGSN) were prepared. The results demonstrated that DPPGSN could be transformed from a negatively charged form into a positively charged form in the slightly acidic tumor extracellular environment. The siRNA targeting MDR1 mRNA (siMDR1) ...
Source: Drug Development and Industrial Pharmacy - September 16, 2020 Category: Drugs & Pharmacology Tags: Drug Dev Ind Pharm Source Type: research

Folic acid (FA)-conjugated mesoporous silica nanoparticles combined with MRP-1 siRNA improves the suppressive effects of myricetin on non-small cell lung cancer (NSCLC)
Publication date: May 2020Source: Biomedicine & Pharmacotherapy, Volume 125Author(s): Yinxue Song, Bin Zhou, Xiangyang Du, Yong Wang, Jie Zhang, Yanqiu Ai, Zongjiang Xia, Gaofeng Zhao
Source: Biomedicine and Pharmacotherapy - February 25, 2020 Category: Drugs & Pharmacology Source Type: research

Folic acid (FA)-conjugated mesoporous silica nanoparticles combined with MRP-1 siRNA improves the suppressive effects of myricetin on non-small cell lung cancer (NSCLC).
Abstract Non-small cell lung cancer (NSCLC) is a common diagnosed cancer disease worldwide and its management remains a challenge. Synergistic cancer therapeutic strategy is interesting for multiple advantages, such as excellent targeting accuracy, low side effects, and promoted therapeutic efficiency. In the present study, myricetin (Myr)-loaded mesoporous silica nanoparticles (MSN) combined with multidrug resistance protein (MRP-1) siRNA was prepared. The surface of the synthesized nanoparticles was modified with folic acid (FA) to promote the therapeutic efficiency of Myr for the treatment of NSCLC. The collect...
Source: Biomedicine and pharmacotherapy = Biomedecine and pharmacotherapie - February 21, 2020 Category: Drugs & Pharmacology Authors: Song Y, Zhou B, Du X, Wang Y, Zhang J, Ai Y, Xia Z, Zhao G Tags: Biomed Pharmacother Source Type: research

Chalcomoracin inhibits cell proliferation and increases sensitivity to radiotherapy in human non-small cell lung cancer cells via inducing endoplasmic reticulum stress-mediated paraptosis.
In this study, we investigated the effects of CMR against human non-small cell lung cancer cells and the underlying mechanisms. We found that CMR dose-dependently inhibited the proliferation of human lung cancer H460, A549 and PC-9 cells. Furthermore, exposure to low and median doses of CMR induced paraptosis but not apoptosis, which was presented as the formation of extensive cytoplasmic vacuolation with increased expression of endoplasmic reticulum stress markers, Bip and Chop, as well as activation of MAPK pathway in the lung cancer cells. Knockdown of Bip with siRNA not only reduced the cell-killing effect of CMR, but ...
Source: Acta Pharmacologica Sinica - February 16, 2020 Category: Drugs & Pharmacology Authors: Zhang SR, Zhang XC, Liang JF, Fang HM, Huang HX, Zhao YY, Chen XQ, Ma SL Tags: Acta Pharmacol Sin Source Type: research

Effects of lncRNA SNHG20 on proliferation and apoptosis of non-small cell lung cancer cells through Wnt/ β-catenin signaling pathway.
CONCLUSIONS: LncRNA SNHG20 promotes the proliferation and inhibits the apoptosis of NSCLC cells by targeting miR-197 through the Wnt/β-catenin signaling pathway. PMID: 31957836 [PubMed - in process]
Source: European Review for Medical and Pharmacological Sciences - January 21, 2020 Category: Drugs & Pharmacology Tags: Eur Rev Med Pharmacol Sci Source Type: research